Cilengitide
Based on 72 publication(s) in Google Scholar
Cilengitide (EMD 121974) is a BBB-permeable integrins antagonist with IC50s of 0.61 nM (ανβ3), 8.4 nM (ανβ5) and 14.9 nM (α5β1), respectively. Cilengitide inhibits the binding of ανβ3 and ανβ5 to Vitronectin with IC50s of 4 nM and 79 nM, respectively. Cilengitide inhibits TGF-β/Smad signaling, mediates PD-L1 expression. Cilengitide also induces apoptosis, shows antiangiogenic effect in the research against glioblastoma and other cancers.
For research use only. We do not sell to patients.
- Purity: 99.91%
- CAS No.: 188968-51-6
- Formula: C27H40N8O7
- Molecular Weight:588.66
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 1 year , -20°C, 6 months
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Apoptosis Compound Library
HY-L003
-
Immunology/Inflammation Compound Library
HY-L007
-
JAK/STAT Compound Library
HY-L008
-
Kinase Inhibitor Library
HY-L009
-
Stem Cell Signaling Compound Library
HY-L017
-
Anti-Cancer Compound Library
HY-L025
-
Clinical Compound Library
HY-L026
-
CNS-Penetrant Compound Library
HY-L028
-
Autophagy Compound Library
HY-L029
-
Small Molecule Immuno-Oncology Compound Library
HY-L031
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Differentiation Inducing Compound Library
HY-L038
-
Macrocyclic Compound Library
HY-L041
-
Anti-COVID-19 Compound Library
HY-L052
-
Cytoskeleton Compound Library
HY-L060
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Obesity Compound Library
HY-L087
-
Transcription Factor-Targeted Library
HY-L090
-
Targeted Diversity Library
HY-L099
-
Anti-Liver Cancer Compound Library
HY-L101
-
Rare Diseases Drug Library
HY-L102
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Protein-protein Interaction Inhibitor Library
HY-L109
-
Human Metabolite Library
HY-L123
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Osteogenesis Compound Library
HY-L131
-
Cancer Stem Cells Compound Library
HY-L135
-
Coagulation and Anti-coagulation Compound Library
HY-L136
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
Extracellular Vesicles (EVs) Compound Library
HY-L168
-
Anti-Hematopathy Compound Library
HY-L171
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
Anti-Aging Compound Library Mini
HY-L034M
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
Anti-Gastric Cancer Compound Library
HY-L184
-
Anti-Brain Cancer Compound Library
HY-L188
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Posttranslational Modification Library
HY-L226
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) Cilengitide
More- Cancer Cell. 2021 Nov 8;39(11):1531-1547.e10. [Abstract]
- Cell. 2020 Aug 6;182(3):545-562.e23. [Abstract]
- Nat Mater. 2025 Sep 1. [Abstract]
- Nat Cell Biol. 2020 Mar;22(3):289-296. [Abstract]
- Adv Sci (Weinh). 2025 Oct 30:e01602. [Abstract]
- Adv Sci (Weinh). 2025 Apr 28:e2504647. [Abstract]
- J Clin Invest. 2025 Oct 16:e188822. [Abstract]
- Chem Eng J. 2025 Dec 20.
- Sci Adv. 2026 Jan 2;12(1):eadx2768. [Abstract]
- Sci Adv. 2026 Jan 2;12(1):eady4112. [Abstract]
- Engineering. 8 October 2020.
- Cell Rep Med. 2025 Jan 16:101922. [Abstract]
- J Immunother Cancer. 2020 Mar;8(1):e000111. [Abstract]
- Int J Biol Sci. 2025 May 27;21(8):3573-3596. [Abstract]
- Cell Death Dis. 2025 Dec 12;16(1):887. [Abstract]
- Cell Death Dis. 2022 Dec 7;13(12):1028. [Abstract]
- Free Radic Biol Med. 2024 Dec 9:227:296-311. [Abstract]
- J Transl Med. 2018 Dec 12;16(1):352. [Abstract]
- Cell Mol Gastroenterol Hepatol. 2025 May 29:101548. [Abstract]
- Oncogene. 2025 Jul;44(28):2396-2412. [Abstract]
- Environ Pollut. 2023 Aug 1:330:121817. [Abstract]
- Cell Rep. 2022 Sep 27;40(13):111422. [Abstract]
- Br J Cancer. 2023 Mar;128(7):1344-1359. [Abstract]
- Clin Transl Med. 2021 Oct;11(10):e548. [Abstract]
- J Cell Biol. 2023 Aug 7;222(8):e202303107. [Abstract]
- Oncoimmunology. 2025 Dec;14(1):2508057. [Abstract]
- Front Immunol. 2018 Jun 1:9:1207. [Abstract]
- Blood Rev. 2023 May:59:101038. [Abstract]
- Biochem Pharmacol. 2025 Jun:236:116870. [Abstract]
- Mol Cancer Ther. 2022 Sep 6;21(9):1485-1496. [Abstract]
- J Chem Inf Model. 2023 Oct 23;63(20):6302-6315. [Abstract]
- Commun Biol. 2024 Dec 30;7(1):1713. [Abstract]
- Stem Cell Reports. 2017 Dec 12;9(6):1948-1960. [Abstract]
- Respir Res. 2025 Jul 2;26(1):229. [Abstract]
- Front Pharmacol. 2021 Feb 24:12:585778. [Abstract]
- Int Immunopharmacol. 2024 Jul 1:138:112545. [Abstract]
- Am J Physiol Cell Physiol. 2018 Apr 1;314(4):C415-C427. [Abstract]
- Obesity. 2015 Apr;23(4):779-85. [Abstract]
- Cancers (Basel). 2023 Mar 12;15(6):1729. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2024 Aug 31:167484. [Abstract]
- FASEB J. 2023 Feb;37(2):e22726. [Abstract]
- Bioengineered. 2022 Feb;13(2):4557-4572. [Abstract]
- J Cell Physiol. 2024 Jun;239(6):e31267. [Abstract]
- Lung. 2020 Dec;198(6):947-955. [Abstract]
- Mol Cell Biochem. 2025 Oct 20. [Abstract]
- Cell Adh Migr. 2019 Dec;13(1):152-163. [Abstract]
- Cell Biol Int. 2020 Apr;44(4):966-974. [Abstract]
- Cancer Med. 2018 Feb;7(2):408-419. [Abstract]
- J Integr Neurosci. 2024 Jul 25;23(7):140. [Abstract]
- Differentiation. 2026 May-Jun:149:100962. [Abstract]
- PLoS One. 2016 Feb 3;11(2):e0148333. [Abstract]
- PLoS One. 2014 Oct 13;9(10):e110453. [Abstract]
- J Oral Pathol Med. 2025 Aug;54(7):597-606. [Abstract]
- Biomed Res Int. 2021 Nov 30:2021:5954757. [Abstract]
- J Mol Histol. 2020 Apr;51(2):147-159. [Abstract]
- Atheroscler Plus. 2022 Oct 19:50:57-64. [Abstract]
- J Vis Exp. 2025 May 23:(219). [Abstract]
- Scand Cardiovasc J. 2021 Oct;55(5):287-296. [Abstract]
- bioRxiv. 2026 Jun 1.
- Universidad de Granada. 2026.
- Res Sq. 2026 Feb 15.
- bioRxiv. 2026 Jan 05.
- bioRxiv. 2025 Sep 21.
- SSRN. 2025 Jul 7.
- medRxiv. 2025 Mar 23.
- SSRN. 2025 Feb 19.
- bioRxiv. 2024 Aug 28:2024.08.27.609975. [Abstract]
- Patent. US20220378739A1.
- Research Square Preprint. 2022 Jan.
- bioRxiv. 2020 Apr.
- Patent. US20180263995A1.
- Santa Clara University. 2014 Jun 12.
Customer Validation & Images
-
WB
-
IHC
-
WB
-
WB
-
Cell Proliferation/Viability Assay
Biological Activity
|
αvβ3 4 nM (IC50, αvβ3-Vitronectin interaction[2]) |
αvβ5 79 nM (IC50, αvβ5-Vitronectin interaction[2]) |
αvβ3 0.61 nM (IC50, [1]) |
αvβ5 8.4 nM (IC50, [1]) |
α5β1 14.9 nM (IC50, [1]) |
STAT3 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | IC50 |
0.54 nM
Compound: Cilengitide
|
Inhibition of vitronectin binding to recombinant human integrin alphaV (Phe31 to Val992 residues) beta3 (Gly27 to Asp718 residues) expressed in CHO cells by ELISA based solid phase binding assay
Inhibition of vitronectin binding to recombinant human integrin alphaV (Phe31 to Val992 residues) beta3 (Gly27 to Asp718 residues) expressed in CHO cells by ELISA based solid phase binding assay
|
[PMID: 32094009] |
| CHO | IC50 |
15.4 nM
Compound: Cilengitide
|
Inhibition of fibronectin binding to recombinant human integrin alpha5 (Phe42 to Tyr995 residues) beta1 (Gln21 to Asp728 residues) expressed in CHO cells by ELISA based solid phase binding assay
Inhibition of fibronectin binding to recombinant human integrin alpha5 (Phe42 to Tyr995 residues) beta1 (Gln21 to Asp728 residues) expressed in CHO cells by ELISA based solid phase binding assay
|
[PMID: 32094009] |
| CHO | IC50 |
8 nM
Compound: Cilengitide
|
Inhibition of vitronectin binding to recombinant human integrin alphaV (Phe31 to Val992 residues) beta5 (Gly24 to Asn719 residues) expressed in CHO cells by ELISA based solid phase binding assay
Inhibition of vitronectin binding to recombinant human integrin alphaV (Phe31 to Val992 residues) beta5 (Gly24 to Asn719 residues) expressed in CHO cells by ELISA based solid phase binding assay
|
[PMID: 32094009] |
| HEK-293T | IC50 |
0.51 nM
Compound: c(RGDfV)
|
Binding affinity to soluble truncated human recombinant Fc-tagged alphaVbeta3 and integrins were expressed in HEK293T cells after 2 hrs by competition ELISA-like assay
Binding affinity to soluble truncated human recombinant Fc-tagged alphaVbeta3 and integrins were expressed in HEK293T cells after 2 hrs by competition ELISA-like assay
|
[PMID: 24095096] |
| M21 | IC50 |
0.4 nM
Compound: c[RGDf(Me)V]; Cilengitide
|
Binding affinity to integrin alphav/beta3 heterodimer in human M21 cells assessed as inhibition of integrin-mediated human M21 cell adhesion to vitronectin after 1 hr in presence of MnCl2
Binding affinity to integrin alphav/beta3 heterodimer in human M21 cells assessed as inhibition of integrin-mediated human M21 cell adhesion to vitronectin after 1 hr in presence of MnCl2
|
[PMID: 26753814] |
| M21 | IC50 |
0.4 μM
Compound: 2
|
Inhibition of integrin alpha-v/beta-3 mediated M21 cell adhesion to vitronectin with monoclonal antibody P1F6
Inhibition of integrin alpha-v/beta-3 mediated M21 cell adhesion to vitronectin with monoclonal antibody P1F6
|
[PMID: 11855984] |
Cilengitide is a cyclized RGD (Arg-Gly-Asp motif)-containing pentapeptide. Cilengitide blocks integrin ανβ3- and ανβ5-mediated endothelial cell attachment and migration[2].
Cilengitide inhibits integrin-mediated binding to Vitronectin with IC50s of 0.4 and 0.4 μM in cell adhesion studies assessing the human melanoma M21 or UCLA-P3 human lung carcinoma cell lines[2].
Cilengitide inhibits the attachment of human umbilical vein endothelial cells to Vitronectin with an IC50 of 2 μM[2].
Cilengitide (0-1 mg/mL; 24-72 h) inhibits cell viability of melanoma cells in vitro and (5 μg/mL; 12 h) induces B16 and A375 cells apoptosis[3].
Cilengitide (5 μg/mL, 10 μg/mL; 2 weeks) inhibits colony formation of B16 and A375 cells[3].
Cilengitide (0-20 μg/mL; 12 h) inhibits STAT3 phosphorylation to decrease the expression of PD-L1[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:B16 and A375 cells
-
Concentration:0, 5, 10, and 20 μg/mL
-
Incubation Time:12 hours
-
Result:Suppressed PD-L1 expression and STAT3 phosphorylation at concentrations greater than 5 µg/mL.
-
Cell Line:B16 and A375 cells
-
Concentration:5 μg/mL
-
Incubation Time:12 hours
-
Result:Resulted apoptosis rates in B16 and A375 cells of 15.27% and 14.89%, respectively.
Cilengitide (50 mg/kg; i.p.; daily) enhances the function of CD8+ T cells and promotes anti-PD1 efficacy with Anti-PD1 monoclonal antibody in B16 murine melanoma model[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nude mice bearing M21-L melanoma tumors[2]
-
Dosage:10, 50, and 250 μg
-
Administration:Dosed i.p. three times per week
-
Result:Demonstrated inhibition of tumor growth with a reduction in both tumor volume (55%, 75%, and 89%, respectively) and tumor weight (23%, 38%, and 61%, respectively), when compared to controls.
-
Animal Model:Female C57BL/6 mice (6-8 weeks old) with B16 cells s.c.[3]
-
Dosage:50 mg/kg; with or without 10 mg/kg Anti-PD1 monoclonal antibody or isotype control i.p. every 3 days;
-
Administration:Intraperitoneal injection; daily
-
Result:Downregulated the expression of PD-L1 via STAT3 pathway and decreased the expression of PD-L1.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 188968-51-6
-
Appearance Solid
-
Molecular Weight 588.66
-
Formula C27H40N8O7
-
Color White to light yellow
-
SMILES
O=C(NCC(N[C@H](C(N[C@H](CC1=CC=CC=C1)C(N([C@H]2C(C)C)C)=O)=O)CC(O)=O)=O)[C@H](CCCNC(N)=N)NC2=O
-
Synonyms
EMD 121974
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 1 year -20°C 6 months
Publications (72)
-
Journal Impact Factor
-
Most Recent
-
Cancer Cell
2021 Nov 8;39(11):1531-1547.e10. PMID: 34624218 -
Cell
2020 Aug 6;182(3):545-562.e23. PMID: 32621799 -
-
Nat Cell Biol
Crosstalk with lung epithelial cells regulates Sfrp2-mediated latency in breast cancer dissemination. [Abstract]2020 Mar;22(3):289-296. PMID: 32094692 -
Adv Sci (Weinh)
Cancer Immunotherapy via Disruption of Integrin αvβ3 and CD47 Costabilization on Cancer Cell Surface. [Abstract]2025 Oct 30:e01602. PMID: 41168993 -
Adv Sci (Weinh)
Drug Screening of Primary Human Endometriotic Cells Based on Micro-Encapsulating Microfluidic Chip. [Abstract]2025 Apr 28:e2504647. PMID: 40289897 -
J Clin Invest
Excessive collagen type VII mediates pleural fibrosis via increasing extracellular matrix stiffness. [Abstract]2025 Oct 16:e188822. PMID: 41100460 -
-
Sci Adv
Dynamic adaptive coassembled sericin protein orchestrating stem cell development for nucleus pulposus regeneration. [Abstract]2026 Jan 2;12(1):eadx2768. PMID: 41477862 -
Sci Adv
Integrin inhibition facilitates fibrocartilaginous transformation in connective tissue in osteoarthritis. [Abstract]2026 Jan 2;12(1):eady4112. PMID: 41481715 -
-
Cell Rep Med
MFGE8 induces anti-PD-1 therapy resistance by promoting extracellular vesicle sorting of PD-L1. [Abstract]2025 Jan 16:101922. PMID: 39842432 -
J Immunother Cancer
Downregulation of RIG-I mediated by ITGB3/c-SRC/STAT3 signaling confers resistance to interferon-α-induced apoptosis in tumor-repopulating cells of melanoma. [Abstract]2020 Mar;8(1):e000111. PMID: 32152220 -
Int J Biol Sci
Integrative Single-Cell and Spatial Transcriptomics Analysis Reveals ECM-remodeling Cancer-associated Fibroblast-Derived POSTN as a Key Mediator in Pancreatic Ductal Adenocarcinoma Progression. [Abstract]2025 May 27;21(8):3573-3596. PMID: 40520021 -
Cell Death Dis
2025 Dec 12;16(1):887. PMID: 41387479 -
Cell Death Dis
Laminins in tumor-derived exosomes upregulated by ETS1 reprogram omental macrophages to promote omental metastasis of ovarian cancer. [Abstract]2022 Dec 7;13(12):1028. PMID: 36477408 -
Free Radic Biol Med
2024 Dec 9:227:296-311. PMID: 39653130 -
J Transl Med
Integrin ανβ5 in vitro inhibition limits pro-fibrotic response in cardiac fibroblasts of spontaneously hypertensive rats. [Abstract]2018 Dec 12;16(1):352. PMID: 30541573
Cilengitide purchased from MedChemExpress. Usage Cited in: J Transl Med. 2018 Dec 12;16(1):352. [Abstract]
Representative images of immunofluorescence performed for α-SMA on WKY- and SHR-CF in the treatment of TGF-β1, cilengitide or both.
Cilengitide purchased from MedChemExpress. Usage Cited in: J Transl Med. 2018 Dec 12;16(1):352. [Abstract]
Representative Western blot images of ανβ5 and collagen I protein expression in WKY- and SHR-CF cultured on substrates with two different stiffness (high and low) and contemporary treated with 5 ng/ml TGF-β1, TGF-β1 + 0.5 μM cilengitide, or cilengitide.
-
Cell Mol Gastroenterol Hepatol
MFAP4 Deficiency Attenuates Liver Fibrosis by Regulating Hepatic Stellate Cell Fate through Inhibition of the FAK/PI3K/NFκB Signaling Pathway. [Abstract]2025 May 29:101548. PMID: 40449846 -
Oncogene
Fibroblast Activation Protein (FAP)+ cancer-associated fibroblasts induce macrophage M2-like polarization via the Fibronectin 1-Integrin α5β1 axis in breast cancer. [Abstract]2025 Jul;44(28):2396-2412. PMID: 40263422 -
Environ Pollut
Low-dose graphene oxide promotes tumor cells proliferation by activating PI3K-AKT-mTOR signaling via cellular membrane protein integrin αV. [Abstract]2023 Aug 1:330:121817. PMID: 37182579 -
Cell Rep
2022 Sep 27;40(13):111422. PMID: 36170814 -
Br J Cancer
Transcriptome analysis of newly established carboplatin-resistant ovarian cancer cell model reveals genes shared by drug resistance and drug-induced EMT. [Abstract]2023 Mar;128(7):1344-1359. PMID: 36717670 -
Clin Transl Med
Targeting integrin αvβ3 with indomethacin inhibits patient-derived xenograft tumour growth and recurrence in oesophageal squamous cell carcinoma. [Abstract]2021 Oct;11(10):e548. PMID: 34709754 -
J Cell Biol
Reticular adhesions are assembled at flat clathrin lattices and opposed by active integrin α5β1. [Abstract]2023 Aug 7;222(8):e202303107. PMID: 37233325 -
Oncoimmunology
Loss of the extracellular protease ADAMTS1 reveals an antitumorigenic program involving the action of NIDOGEN-1 on macrophage polarization. [Abstract]2025 Dec;14(1):2508057. PMID: 40401531 -
Front Immunol
Adaptive Regulation of Osteopontin Production by Dendritic Cells Through the Bidirectional Interaction With Mesenchymal Stromal Cells. [Abstract]2018 Jun 1:9:1207. PMID: 29910810 -
Blood Rev
Fetal and neonatal alloimmune thrombocytopenia: Current pathophysiological insights and perspectives for future diagnostics and treatment. [Abstract]2023 May:59:101038. PMID: 36581513 -
Biochem Pharmacol
Irisin alleviates steroid-induced vascular dysfunction by regulating the αVβ5-c-Abl-Caveolin-1 signaling pathway. [Abstract]2025 Jun:236:116870. PMID: 40086515 -
Mol Cancer Ther
Inhibition of Integrin αVβ3 Signaling Improves the Antineoplastic Effect of Bexarotene in Cutaneous T-Cell Lymphoma. [Abstract]2022 Sep 6;21(9):1485-1496. PMID: 35793463 -
J Chem Inf Model
Molecular View on the i RGD Peptide Binding Mechanism: Implications for Integrin Activity and Selectivity Profiles. [Abstract]2023 Oct 23;63(20):6302-6315. PMID: 37788340 -
Commun Biol
Abnormal cytoskeletal remodeling but normal neuronal excitability in a mouse model of the recurrent developmental and epileptic encephalopathy-susceptibility KCNB1-p.R312H variant. [Abstract]2024 Dec 30;7(1):1713. PMID: 39738805 -
Stem Cell Reports
Inhibition of Farnesyltransferase Potentiates NOTCH-Targeted Therapy against Glioblastoma Stem Cells. [Abstract]2017 Dec 12;9(6):1948-1960. PMID: 29198824 -
Respir Res
The MFGE8/integrin β3 axis mitigates experimental neutrophilic asthma by suppressing NLRP3-Caspase-1 pathway-mediated NETosis. [Abstract]2025 Jul 2;26(1):229. PMID: 40605028 -
Front Pharmacol
Antagonizing αvβ3 Integrin Improves Ischemia-Mediated Vascular Normalization and Blood Perfusion by Altering Macrophages. [Abstract]2021 Feb 24:12:585778. PMID: 33716733 -
Int Immunopharmacol
Irisin attenuates acute glaucoma-induced neuroinflammation by activating microglia-integrin αVβ5/AMPK and promoting autophagy. [Abstract]2024 Jul 1:138:112545. PMID: 38955026 -
Am J Physiol Cell Physiol
Expression of CTGF/CCN2 in response to LPA is stimulated by fibrotic extracellular matrix via the integrin/FAK axis. [Abstract]2018 Apr 1;314(4):C415-C427. PMID: 29351412
Cilengitide purchased from MedChemExpress. Usage Cited in: Am J Physiol Cell Physiol. 2018 Apr 1;314(4):C415-C427. [Abstract]
C2C12 cells are pre-incubated with different concentrations of Cilengitide prior to LPA 20 μg/mL addition and incubation for 3 hours. CTGF levels are analyzed.
-
Obesity
Immunological blockade of adipocyte inflammation caused by increased matrix metalloproteinase-cleaved osteopontin in obesity. [Abstract]2015 Apr;23(4):779-85. PMID: 25776538 -
Cancers (Basel)
Sandwich Culture Platforms to Investigate the Roles of Stiffness Gradients and Cell-Matrix Adhesions in Cancer Cell Migration. [Abstract]2023 Mar 12;15(6):1729. PMID: 36980615 -
Biochim Biophys Acta Mol Basis Dis
CCL2/CCR2 axis promotes perineural invasion of salivary adenoid cystic carcinoma via ITGβ5-mediated nerve-tumor interaction. [Abstract]2024 Aug 31:167484. PMID: 39222826 -
FASEB J
Periostin increased by mechanical stress upregulates interleukin-6 expression in the ligamentum flavum. [Abstract]2023 Feb;37(2):e22726. PMID: 36583686 -
Bioengineered
Cilengitide, an αvβ3-integrin inhibitor, enhances the efficacy of anti-programmed cell death-1 therapy in a murine melanoma model. [Abstract]2022 Feb;13(2):4557-4572. PMID: 35142593 -
J Cell Physiol
FNDC5 inhibits malignant growth of human cervical cancer cells via restraining PI3K/AKT pathway. [Abstract]2024 Jun;239(6):e31267. PMID: 38558303 -
Lung
The Integrin Inhibitor Cilengitide and Bleomycin-Induced Pulmonary Fibrosis : Cilengitide and Bleomycin-Induced Pulmonary Fibrosis. [Abstract]2020 Dec;198(6):947-955. PMID: 33146772 -
Mol Cell Biochem
Irisin protects against atherosclerosis in ApoE-/- mice by suppressing the migration of vascular smooth muscle cell via PI3K-Akt-cofilin. [Abstract]2025 Oct 20. PMID: 41114763 -
Cell Adh Migr
Fluid shear stress induces cell migration and invasion via activating autophagy in HepG2 cells. [Abstract]2019 Dec;13(1):152-163. PMID: 30663937
Cilengitide purchased from MedChemExpress. Usage Cited in: Cell Adh Migr. 2019 Dec;13(1):152-163. [Abstract]
HepG2 cells are loaded with FSS at 1 dyn/cm2 for 0.5 h, with or without treatment of 0.5 μM Cli for 6 h prior to FSS application. Lysates are probed with antibodies as indicated.
-
Cell Biol Int
Protective effects of cilengitide on inflammation in chondrocytes under excessive mechanical stress. [Abstract]2020 Apr;44(4):966-974. PMID: 31876323 -
Cancer Med
The synergistic role of ATP-dependent drug efflux pump and focal adhesion signaling pathways in vinorelbine resistance in lung cancer. [Abstract]2018 Feb;7(2):408-419. PMID: 29318780 -
J Integr Neurosci
Milk Fat Globule-EGF Factor 8 (MFGE8) Mitigates Cognitive Impairment in Rats with Sepsis-Associated Encephalopathy: An fMRI Study. [Abstract]2024 Jul 25;23(7):140. PMID: 39082291 -
Differentiation
Osteoclast-derived DEL1 promotes pathological bone formation in ankylosing spondylitis by regulating RUNX2 expression in osteoblasts. [Abstract]2026 May-Jun:149:100962. PMID: 42128469 -
PLoS One
Inhibition of Cellular Adhesion by Immunological Targeting of Osteopontin Neoepitopes Generated through Matrix Metalloproteinase and Thrombin Cleavage. [Abstract]2016 Feb 3;11(2):e0148333. PMID: 26840958
Cilengitide purchased from MedChemExpress. Usage Cited in: PLoS One. 2016 Feb 3;11(2):e0148333. [Abstract]
Blockade of cellular adhesion of HEK 293 cells at 10 or 30 nM coated recombinant OPN forms with 1μM antagonistic integrin inhibitors. RGES (black bars) is used as a control peptide. Cilengitide (white bars) inhibits the integrins αVβ3, αVβ5, and α5β1. TR-14035 (hatched bars) inhibits the integrins α4β7 and α4β1. Depicted are the means ± SEM of 3 independent experiments. * indicate signif
-
PLoS One
A novel 2.5D culture platform to investigate the role of stiffness gradients on adhesion-independent cell migration. [Abstract]2014 Oct 13;9(10):e110453. PMID: 25310593 -
J Oral Pathol Med
2025 Aug;54(7):597-606. PMID: 40589419 -
Biomed Res Int
Cilengitide Inhibits Neovascularization in a Rabbit Abdominal Aortic Plaque Model by Impairing the VEGF Signaling. [Abstract]2021 Nov 30:2021:5954757. PMID: 34888383 -
J Mol Histol
Gingipains promote RANKL-induced osteoclastogenesis through the enhancement of integrin β3 in RAW264.7 cells. [Abstract]2020 Apr;51(2):147-159. PMID: 32193744 -
Atheroscler Plus
Periostin contributes to the adventitial remodeling of atherosclerosis by activating adventitial fibroblasts. [Abstract]2022 Oct 19:50:57-64. PMID: 36643802 -
J Vis Exp
2025 May 23:(219). PMID: 40489409 -
Scand Cardiovasc J
Dual integrin αvβ3 and αvβ5 blockade attenuates cardiac dysfunction by reducing fibrosis in a rat model of doxorubicin-induced cardiomyopathy. [Abstract]2021 Oct;55(5):287-296. PMID: 34296634 -
-
-
-
-
-
-
-
-
bioRxiv
Cancer-associated fibroblasts confer ALK inhibitor resistance in EML4-ALK -driven lung cancer via concurrent integrin and MET signaling. [Abstract]2024 Aug 28:2024.08.27.609975. PMID: 39253447 -
-
-
-
-
Cilengitide purchased from MedChemExpress. Usage Cited in: Santa Clara University. 2014 Jun 12.
Cilengitide Photos: Pictures of migration through alginate with and without Cilengitide after four days. A) The view of the bottom of the untreated well, showing a healthy monolayer of U87s. B) The view of the cells suspended in alginate in the untreated well. A few of the multiple migrated cells within the image are marked with arrows. C) The view of the bottom of the Cilengitide treated well, showing very few, ill-attached U87s. D). The view of cells suspended in alginate in the Cilengitide-tr
Solvent & Solubility
DMSO : ≥ 44 mg/mL (74.75 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 35 mg/mL (59.46 mM; Need ultrasonic)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (169.88 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Purity & Documentation
-
Data Sheet (285 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
[1]. Kapp TG, et al. A Comprehensive Evaluation of the Activity and Selectivity Profile of Ligands for RGD-binding Integrins. Sci Rep. 2017 Jan 11;7:39805. [Content Brief]
[2]. Hariharan S, et al. Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrinreceptor antagonist, Cilengitide (EMD 121974), in patients with advanced solid tumors. Ann Oncol. 2007 Aug;18(8):1400-7. [Content Brief]
[3]. Pan X, et al. Cilengitide, an αvβ3-integrin inhibitor, enhances the efficacy of anti-programmed cell death-1 therapy in a murine melanoma model. Bioengineered. 2022 Feb;13(2):4557-4572. [Content Brief]
[4]. MacDonald TJ, et al. Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol. 2008 Feb 20;26(6):919-24. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 1.6988 mL | 8.4939 mL | 16.9877 mL | 42.4693 mL |
| 5 mM | 0.3398 mL | 1.6988 mL | 3.3975 mL | 8.4939 mL | |
| 10 mM | 0.1699 mL | 0.8494 mL | 1.6988 mL | 4.2469 mL | |
| 15 mM | 0.1133 mL | 0.5663 mL | 1.1325 mL | 2.8313 mL | |
| 20 mM | 0.0849 mL | 0.4247 mL | 0.8494 mL | 2.1235 mL | |
| 25 mM | 0.0680 mL | 0.3398 mL | 0.6795 mL | 1.6988 mL | |
| 30 mM | 0.0566 mL | 0.2831 mL | 0.5663 mL | 1.4156 mL | |
| 40 mM | 0.0425 mL | 0.2123 mL | 0.4247 mL | 1.0617 mL | |
| 50 mM | 0.0340 mL | 0.1699 mL | 0.3398 mL | 0.8494 mL | |
| DMSO | 60 mM | 0.0283 mL | 0.1416 mL | 0.2831 mL | 0.7078 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz